Sei Investments Co. increased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 23.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,488 shares of the medical research company’s stock after buying an additional 19,419 shares during the quarter. Sei Investments Co. owned about 0.06% of Bruker worth $3,019,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Teachers Advisors LLC boosted its holdings in shares of Bruker by 20.5% in the 1st quarter. Teachers Advisors LLC now owns 148,229 shares of the medical research company’s stock valued at $3,458,000 after purchasing an additional 25,225 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Bruker by 7.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 944,553 shares of the medical research company’s stock valued at $22,034,000 after acquiring an additional 66,344 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Bruker by 106.6% during the 1st quarter. Renaissance Technologies LLC now owns 59,110 shares of the medical research company’s stock valued at $1,379,000 after acquiring an additional 30,500 shares in the last quarter. KCG Holdings Inc. bought a new position in Bruker during the 1st quarter worth $217,000. Finally, Aperio Group LLC raised its position in Bruker by 9.6% during the 2nd quarter. Aperio Group LLC now owns 19,362 shares of the medical research company’s stock worth $558,000 after purchasing an additional 1,699 shares during the last quarter. 65.63% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bruker Co. (NASDAQ BRKR) traded up $0.63 during mid-day trading on Friday, reaching $34.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. Bruker Co. has a twelve month low of $21.03 and a twelve month high of $36.53. The firm has a market cap of $5,416.70, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.94 and a beta of 1.12.
Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 10.6% on a year-over-year basis. research analysts anticipate that Bruker Co. will post 1.19 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be given a dividend of $0.04 per share. The ex-dividend date is Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.46%. Bruker’s payout ratio is 17.02%.
Several brokerages recently issued reports on BRKR. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Wednesday, November 8th. Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a research report on Friday, November 3rd. Cowen reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker in a research report on Friday, November 3rd. J P Morgan Chase & Co raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a research report on Friday, November 3rd. Finally, Goldman Sachs Group reiterated a “sell” rating and set a $24.00 price target on shares of Bruker in a research note on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $29.64.
In other Bruker news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the sale, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 35.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sei Investments Co. Has $3.02 Million Holdings in Bruker Co. (BRKR)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/10/sei-investments-co-grows-holdings-in-bruker-co-brkr.html.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.